- Home
- AGEN vs RVSB Comparison
AGEN vs RVSB Comparison
Compare AGEN & RVSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- RVSB
- Stock Information
- Founded
- AGEN 1994
- RVSB 1923
- Country
- AGEN United States
- RVSB United States
- Employees
- AGEN N/A
- RVSB N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- RVSB Savings Institutions
- Sector
- AGEN Health Care
- RVSB Finance
- Exchange
- AGEN Nasdaq
- RVSB Nasdaq
- Market Cap
- AGEN 126.8M
- RVSB 110.2M
- IPO Year
- AGEN 2000
- RVSB 1993
- Fundamental
- Price
- AGEN $4.29
- RVSB $5.13
- Analyst Decision
- AGEN Buy
- RVSB Buy
- Analyst Count
- AGEN 2
- RVSB 1
- Target Price
- AGEN $14.50
- RVSB $7.00
- AVG Volume (30 Days)
- AGEN 460.1K
- RVSB 45.1K
- Earning Date
- AGEN 11-10-2025
- RVSB 10-28-2025
- Dividend Yield
- AGEN N/A
- RVSB 1.55%
- EPS Growth
- AGEN N/A
- RVSB 361.12
- EPS
- AGEN N/A
- RVSB 0.22
- Revenue
- AGEN $106,829,000.00
- RVSB $52,756,000.00
- Revenue This Year
- AGEN $60.49
- RVSB $10.25
- Revenue Next Year
- AGEN N/A
- RVSB $11.23
- P/E Ratio
- AGEN N/A
- RVSB $23.39
- Revenue Growth
- AGEN N/A
- RVSB 15.20
- 52 Week Low
- AGEN $1.38
- RVSB $4.74
- 52 Week High
- AGEN $7.34
- RVSB $6.59
- Technical
- Relative Strength Index (RSI)
- AGEN 54.02
- RVSB 44.09
- Support Level
- AGEN $4.17
- RVSB $5.05
- Resistance Level
- AGEN $4.60
- RVSB $5.45
- Average True Range (ATR)
- AGEN 0.28
- RVSB 0.16
- MACD
- AGEN 0.04
- RVSB -0.03
- Stochastic Oscillator
- AGEN 61.32
- RVSB 11.82
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About RVSB Riverview Bancorp Inc
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.